MLLCF
Price
$4.22
Change
-$0.00 (-0.00%)
Updated
Apr 25 closing price
Capitalization
139.18M
URGN
Price
$13.58
Change
+$0.62 (+4.78%)
Updated
Jul 3 closing price
Capitalization
626.14M
44 days until earnings call
Interact to see
Advertisement

MLLCF vs URGN

Header iconMLLCF vs URGN Comparison
Open Charts MLLCF vs URGNBanner chart's image
Molecular Partners AG
Price$4.22
Change-$0.00 (-0.00%)
Volume$1.33K
Capitalization139.18M
UroGen Pharma
Price$13.58
Change+$0.62 (+4.78%)
Volume$737.41K
Capitalization626.14M
MLLCF vs URGN Comparison Chart in %
Loading...
URGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MLLCF vs. URGN commentary
Jul 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MLLCF is a Hold and URGN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 07, 2025
Stock price -- (MLLCF: $4.22 vs. URGN: $13.58)
Brand notoriety: MLLCF and URGN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MLLCF: 100% vs. URGN: 20%
Market capitalization -- MLLCF: $137.67M vs. URGN: $626.14M
MLLCF [@Biotechnology] is valued at $137.67M. URGN’s [@Biotechnology] market capitalization is $626.14M. The market cap for tickers in the [@Biotechnology] industry ranges from $316.35B to $0. The average market capitalization across the [@Biotechnology] industry is $2.39B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MLLCF’s FA Score shows that 0 FA rating(s) are green whileURGN’s FA Score has 0 green FA rating(s).

  • MLLCF’s FA Score: 0 green, 5 red.
  • URGN’s FA Score: 0 green, 5 red.
According to our system of comparison, MLLCF is a better buy in the long-term than URGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

URGN’s TA Score shows that 6 TA indicator(s) are bullish.

  • URGN’s TA Score: 6 bullish, 4 bearish.

Price Growth

MLLCF (@Biotechnology) experienced а 0.00% price change this week, while URGN (@Biotechnology) price change was +3.59% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

URGN is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
URGN($626M) has a higher market cap than MLLCF($139M). URGN YTD gains are higher at: 27.512 vs. MLLCF (2.676). MLLCF has higher annual earnings (EBITDA): -57.15M vs. URGN (-119.79M). URGN has more cash in the bank: 196M vs. MLLCF (131M). MLLCF has less debt than URGN: MLLCF (2.14M) vs URGN (125M). URGN has higher revenues than MLLCF: URGN (91.9M) vs MLLCF (2.23M).
MLLCFURGNMLLCF / URGN
Capitalization139M626M22%
EBITDA-57.15M-119.79M48%
Gain YTD2.67627.51210%
P/E RatioN/AN/A-
Revenue2.23M91.9M2%
Total Cash131M196M67%
Total Debt2.14M125M2%
FUNDAMENTALS RATINGS
MLLCF vs URGN: Fundamental Ratings
MLLCF
URGN
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
73
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
6035
P/E GROWTH RATING
1..100
88100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MLLCF's Valuation (35) in the null industry is somewhat better than the same rating for URGN (73) in the Biotechnology industry. This means that MLLCF’s stock grew somewhat faster than URGN’s over the last 12 months.

MLLCF's Profit vs Risk Rating (100) in the null industry is in the same range as URGN (100) in the Biotechnology industry. This means that MLLCF’s stock grew similarly to URGN’s over the last 12 months.

MLLCF's SMR Rating (96) in the null industry is in the same range as URGN (100) in the Biotechnology industry. This means that MLLCF’s stock grew similarly to URGN’s over the last 12 months.

URGN's Price Growth Rating (35) in the Biotechnology industry is in the same range as MLLCF (60) in the null industry. This means that URGN’s stock grew similarly to MLLCF’s over the last 12 months.

MLLCF's P/E Growth Rating (88) in the null industry is in the same range as URGN (100) in the Biotechnology industry. This means that MLLCF’s stock grew similarly to URGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MLLCFURGN
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
N/A
Bullish Trend 4 days ago
75%
Momentum
ODDS (%)
N/A
Bearish Trend 4 days ago
88%
MACD
ODDS (%)
N/A
Bullish Trend 4 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
49%
Bullish Trend 4 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
46%
Bullish Trend 4 days ago
78%
Advances
ODDS (%)
N/A
Bullish Trend 7 days ago
81%
Declines
ODDS (%)
N/A
Bearish Trend 5 days ago
87%
BollingerBands
ODDS (%)
N/A
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
N/A
Bullish Trend 4 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
URGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EKJYX14.440.19
+1.33%
Allspring Premier Large Co Gr Inst
JGMRX23.700.22
+0.94%
Janus Henderson Triton R
MEMLX14.770.11
+0.75%
Morgan Stanley Inst EMkts Ldrs C
RYPIX61.390.16
+0.26%
Rydex Transportation Inv
FCENX13.850.01
+0.07%
Franklin International Core Equity Adv

MLLCF and

Correlation & Price change

A.I.dvisor indicates that over the last year, MLLCF has been loosely correlated with ENSC. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if MLLCF jumps, then ENSC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MLLCF
1D Price
Change %
MLLCF100%
N/A
ENSC - MLLCF
37%
Loosely correlated
+1.76%
CYYNF - MLLCF
31%
Poorly correlated
N/A
HNSBF - MLLCF
27%
Poorly correlated
N/A
URGN - MLLCF
26%
Poorly correlated
+4.78%
GNPX - MLLCF
24%
Poorly correlated
-3.59%
More